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The Epstein-Barr Virus BamHI C Promoter Is Not Essential for B Cell
Immortalization In Vitro, but It Greatly Enhances B Cell Growth
Transformation
Rosemary J. Tierney, Jasdeep Nagra, Martin Rowe, Andrew I. Bell, Alan B. Rickinson
School of Cancer Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
ABSTRACT
Epstein-Barr virus (EBV) infection of B cells leads to the sequential activation of two viral promoters, Wp and Cp, resulting in
the expression of six EBV nuclear antigens (EBNAs) and the viral Bcl2 homologue BHRF1. The viral transactivator EBNA2 is
required for this switch fromWp to Cp usage during the initial stages of infection. EBNA2-dependent Cp transcription is medi-
ated by the EBNA2 response element (E2RE), a region that contains at least two binding sites for cellular factors; one of these
sites, CBF1, interacts with RBP-JK, which then recruits EBNA2 to the transcription initiation complex. Here we demonstrate
that the B cell-specific transcription factor BSAP/Pax5 binds to a second site, CBF2, in the E2RE. Deletion of the E2RE in the con-
text of a recombinant virus greatly diminished levels of Cp-initiated transcripts during the initial stages of infection but did not
affect the levels ofWp-initiated transcripts or EBNAmRNAs. Consistent with this finding, viruses deleted for the E2RE were not
markedly impaired in their ability to induce B cell transformation in vitro. In contrast, a larger deletion of the entire Cp region
did reduce EBNAmRNA levels early after infection and subsequently almost completely ablated lymphoblastoid cell line (LCL)
outgrowth. Notably, however, rare LCLs could be established following infection with Cp-deleted viruses, and these were indis-
tinguishable fromwild-type-derived LCLs in terms of steady-state EBV gene transcription. These data indicate that, unlikeWp,
Cp is dispensable for the virus’ growth-transforming activity.
IMPORTANCE
Epstein-Barr virus (EBV), a B lymphotropic herpesvirus etiologically linked to several B cell malignancies, efficiently induces B
cell proliferation leading to the outgrowth of lymphoblastoid cell lines (LCLs). The initial stages of this growth-transforming
infection are characterized by the sequential activation of two viral promoters, Wp and Cp, both of which appear to be preferen-
tially active in target B cells. In this work, we have investigated the importance of Cp activity in initiating B cell proliferation and
maintaining LCL growth. Using recombinant viruses, we demonstrate that while Cp is not essential for LCL outgrowth in vitro,
it enhances transformation efficiency by>100-fold. We also show that Cp, likeWp, interacts with the B cell-specific activator
protein BSAP/Pax5. We suggest that EBV has evolved this two-promoter system to ensure efficient colonization of the host B cell
system in vivo.
Epstein-Barr virus (EBV), a lymphotropic herpesvirus linked toa number of human lymphomas, efficiently transforms resting
B cells in vitro into permanent lymphoblastoid cell lines (LCLs).
Such LCLs are driven to continuously proliferate through the co-
ordinated action of a limited set of viral genes; these include the six
nuclear antigens (EBNA1, -2, -3A, -3B, -3C, and -LP), the viral
Bcl2 homologue BHRF1, three latent membrane proteins (LMPs)
(LMP1, LMP2A, and LMP2B), two small nonpolyadenylated
EBV-encoded RNAs (EBERs), and series of microRNAs (miRNAs)
(1). The early stages of this B cell transformation process are char-
acterized by the sequential activation of two viral promoters (2).
The initiating event is the activation ofWp, a viral promoter pres-
ent in each of the 4 to 8 tandemly arranged BamHI W repeats,
which is dependent on the B cell-specific transcription factor BSAP/
Pax5 (3). At early time points, these Wp-initiated transcripts lead to
the expression of BHRF1 and the two nuclear antigens EBNA2 and
EBNA-LP. Subsequently, EBNA2 transactivates an alternative EBNA
promoter, Cp, and this switch in promoter usage is accompanied by
the expression of the remaining nuclear antigens EBNA1, EBNA3A,
EBNA3B, and EBNA3C and the LMPs (1).
Much work has focused on the identification of sequences that
govern Cp activity in infected B cells. Of these, the EBNA2 re-
sponse element (E2RE) situated between positions 429 and
245 relative to the Cp transcription start site is the most critical
(4–7). Genetic and biochemical studies have defined two binding
sites within the E2RE, termed CBF1 and CBF2, which interact
with cellular transcription factors (4, 8). Several groups demon-
strated that the CBF1 site binds RBP-JK (9–12), a component of
the Notch signaling pathway. RBP-JK subsequently recruits
EBNA2 to the promoter, which simultaneously abrogates the
RBP-JK-mediated repression of Cp while stimulating viral tran-
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scription through the EBNA2 transactivation domain (11, 13, 14).
While the CBF2 site has been less well characterized, one study
reported that this sequence interacts with the AU-rich element
RNA binding protein 1 (AUF1), also known as heterogeneous
nuclear ribonucleoprotein D (hnRNPD) (15). In addition, early
DNase I footprinting studies revealed that the E2RE sequence
from positions362 to327, which includes the CBF2 site, was
specifically protected by an unidentified B lymphocyte-specific
transcription factor (7). Taken together with the observation
from in vitro reporter assays that Cp, like Wp, is preferentially
active in B cells (16), these findings suggest that a B cell-specific
factor may regulate Cp activity. However, both RBP-JK and
AUF1 are ubiquitously expressed, and therefore, this B cell
specificity remains unexplained. Other studies have also iden-
tified a number of promoter-proximal sequences critical for Cp
activity. These include sites for NF-Y, Sp1, and C/EBP, which
contribute to EBNA1-dependent activation of Cp (17, 18);
E2F1, ARID3A/Bright, and Oct-2, which act as a bridging com-
plex between Cp and oriP-bound EBNA1 (19); and the cell
cycle regulatory proteins E2F1 and Rb, which interact with the
histone H3K4 demethylase LSD1 (20).
While the above-described studies have been invaluable in
identifying factors that regulate Cp activity, it remains unclear to
what extent Cp is required for the virus’ B cell growth-transform-
ing activity. In this context, we previously used recombinant EBV
technology to demonstrate that a functional Wp is absolutely re-
quired to initiate B cell growth transformation and for the out-
growth of virus-transformed LCLs. In contrast, previous studies
with recombinant EBV genomes lacking either the entire Cp pro-
moter or just the E2RE indicated that Cp is dispensable for LCL
formation (21–24). However, many of the previous Cp studies
used recombinant viruses generated by linked transformation
marker rescue of the nontransforming P3HR1 virus, in which the
EBNA2 deletion was repaired at the same time as the introduction
of Cp mutations. Notably, this approach is unable to investigate
the early events during the infection process or quantitatively
measure the effects of Cp mutations on B cell transformation ef-
ficiency, because of the lack of productively infected cell lines car-
rying the recombinant EBV genomes.
Following our own finding that Wp activity is dependent on
BSAP/Pax5 (3), the present work reexamines the B cell-specific
nature of Cp andmore accurately quantifies the role of Cp during
B cell transformation. To this end, we used the B95.8 strain-de-
rived 2089 bacterial artificial chromosome (BAC) system (25) to
generate recombinant viruses with defined deletions within the
Cp region. Our findings indicate that viral sequences in addition
to the E2RE appear to contribute to Cp activation in the context of
the virus genome and that while Cp is not absolutely essential for
B cell transformation, Cp activity greatly enhances the efficient
outgrowth of EBV-transformed LCLs.
MATERIALS AND METHODS
Ethics statement.This researchwas approved by the BlackCountryCom-
mittee of the United Kingdom National Research Ethics Service (REC
reference number 14/WM/0001).
Electrophoretic mobility shift assays (EMSAs). The preparation of
nuclear extracts and the in vitro binding assay conditions were described
previously (26). The E2RE probe was a [-32P]ATP-end-labeled PCR-
generated sequence corresponding to nucleotides430 to330 relative
to the Cp transcription start site. The wild-type and mutant RBP-JK
(CBF1) and CBF2 binding site sequences used as competitors were de-
scribed previously (8, 27). Supershift reactions were carried out with a
goat polyclonal BSAP (Pax5 [C-20]) antibody (Santa Cruz Biotechnol-
ogy) (28). In vitro-translated (IVT) proteins were generated from plas-
mids pSG5-BSAP (29) and pu1093-5 (RBP-JK) (30) by using the TNT
rabbit reticulocyte system (Promega).
Recombinant viruses.Recombinant EBV genomes containing Cp de-
letions were created from the B95.8 strain-derived EBV BAC construct
2089 (25) and its 2W derivative (31) by homologous recombination.
Shuttle vectors designed to delete the entire Cp promoter region from
positions 429 to 846 (Cp knockout [CpKO]) or just the E2RE se-
quences from positions429 to245 (CpE2REKO) were created from a
pBluescript vector, pBS-Cp, containing BamHI C sequences from posi-
tions 7315 to 14558 (32) and a tetracycline resistance cassette. pBS-CpKO
was created by deleting the EagI-MscI fragment (positions10801 to
12190) (32), while pBS-CpE2REKOwasmade by deletion of the EagI-SacI
fragment (positions 10801 to 11089). The flanking sequences acted as
regions for homologous recombination with the relevant BAC following
their introduction into recombinase-expressing Escherichia coli (33). As a
control, a revertant virus containing awild-typeCp sequencewasmade by
homologous recombination between pBS-Cp and the 8W-CpKO BAC.
BAC integrity and the number ofW repeats were confirmed by restriction
enzyme digestion and visualization of bands on ethidium bromide-
stained 0.8% agarose gels following either standard or field inversion gel
electrophoresis.
The recombinant BACs were transfected into HEK-293 cells by using
Lipofectamine 2000 (Invitrogen), and clones were selected in the presence
of 100 g/ml hygromycin B. Individual clones were selected for their
ability to produce high titers of virus following transfection and induction
of the lytic cycle with BZLF1 and BALF4 expression plasmids. Virus su-
pernatants were harvested and purified by density gradient centrifugation
(Optiprep; Axis Shield), and virus titrationwas carried out by using quan-
titative PCR (QPCR) as previously described (34).
B cell infection. B cells were positively selected from apheresis cones
(National Health Service Blood and Transplant [NHSBT], Birmingham,
United Kingdom) by using CD19 Dynabeads (Invitrogen), followed by
detachment with CD19Detachabead (Invitrogen), according to theman-
ufacturer’s protocols. Isolated B cells were incubated overnight with re-
combinant virus preparations at a knownmultiplicity of infection (MOI).
The attachment of the recombinant virus to B cells was assessed by bind-
ing assays, as previously described (35).
Analysis of EBV gene transcription. RNAwas prepared from cells by
using a Nucleospin II kit (Fisher). Residual genomic DNA was removed
by using a DNA-free kit (Ambion), and cDNAwas synthesized by using a
QScript kit (VWR), according to the manufacturers’ instructions. EBV
transcripts were measured in aliquots of cDNA by using either a standard
96-well QPCR assay format (36) or a high-throughput 48:48 Dynamic
Array Integrated Fluidics Circuit (Fluidigm) (37). For 48:48 arrays, cDNA
samples were subjected to an initial 12 rounds of preamplification with
primers directed against 45 EBV and 3 endogenous control human cellu-
lar sequences. TheQPCRarraywas then performed on a 1-in-5 dilution of
the preamplified product in a Biomark HD instrument (Fluidigm), using
primers and probes directed toward the same 48 target sequences. The data
were analyzed with Biomark real-time PCR analysis software, version 2.0
(Fluidigm). In both standard and 48:48 array QPCR experiments, the AQ
plasmid (37), containing a single copyof each amplicon,was used to generate
standard curves, permitting absolute quantification of transcript numbers.
Transformation assays. B cell transformation assays were carried out
in 96-well plates with fixed cell numbers and various virus doses, as pre-
viously described, and wells with growing colonies were scored after 6
weeks (3, 31).
RESULTS
The B cell-specific activator protein BSAP/Pax5 binds to the Cp
promoter. While a number of transcription factors have been
shown to be involved in the regulation of Cp (Fig. 1A), themolec-
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ular basis of the preferential B cell-specific activity of Cp described
in the literature (6, 16) and confirmedby our ownunpublishedCp
reporter assays is currently unclear. Since our previous studies
showed that the B cell specificity of Wp was mediated by BSAP/
Pax5 (3, 28), we considered whether the same factor also inter-
acted with Cp sequences.
The transcription factor BSAP/Pax5 plays an essential role in B
cell development and is expressed from the pro-B cell stage
through to the mature B cell stage but is absent in terminally
differentiated plasma cells (38–41). Interestingly, a previously re-
portedDNase I footprinting analysis suggested that a region of the
E2RE spanning the CBF2 site interacted with a B cell-restricted
factor. Notably, the CBF2 binding site in Cp bears striking se-
quence similarity to the high-affinity BSAP binding site D within
Wp (Fig. 1B, boldface type) as well as homology to the H2B2.1
BSAP binding site, the low-affinity BSAP site B in Wp, and the
published degenerate BSAP consensus sequence (Fig. 1B, gray
shading) (42). We therefore carried out a series of EMSAs to de-
termine whether BSAP/Pax5 bound to the Cp promoter (Fig. 1C).
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FIG 1 BSAP/Pax5 interacts with the CBF2 binding site. (A) Schematic representation of the linear EBV genome indicating themultiple repeats of the BamHIW
region, each containing a copy of Wp, and the second upstream EBNA promoter Cp. Also shown are the locations of the EBV latent genes, the latent origin of
replication (oriP), and the terminal repeats (TR). The inset is a schematic illustration of the Cp/Wp region indicating the relative positions of known cellular
transcription factors. (B) Alignment of the BSAP/Pax5 consensus binding sequence with BSAP/Pax5 binding sites from the H2B 2.1 promoter, low-affinity Wp
site B, high-affinity EBV Wp site D, and the Cp CBF2 binding site. Shaded nucleotides indicate positions conserved in the BSAP/Pax5 consensus, while
nucleotides in boldface type are conserved betweenWp siteD andCBF2. (C) Protein-DNA complexes formed by incubating the 100-bp radiolabeled E2RE probe
with nuclear extracts from either the T cell line CEM or the B cell line Rael-BL, either alone () or in the presence of the indicated oligonucleotide competitors.
Supershifts were performed by the addition of a Pax5 antibody. The last three tracks indicate protein-DNA complexes formed by incubating the E2RE probewith
IVT RBP-JK and BSAP proteins. Ab, antibody.
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derived from a non-B cell line, CEM, led to the formation of a
single protein-DNA complex, C1, whereas incubation with nu-
clear extract from a B cell line, Rael, yielded the same complex and
two additional slower-migrating complexes, C2 and C3. This cell
type-specific pattern of protein-DNA complexes was confirmed
by using nuclear extracts from four other non-B cell lines and six
additional B cell lines (data not shown). The formation of this C1
complex seen in both CEM and Rael nuclear extracts was totally
blocked by preincubation with the RBP-JK/CBF1 oligonucleotide
competitor but not themutated RBP-JKmut or CBF2 competitor.
Thus, the C1 complex likely corresponds to the ubiquitous factor
RBP-JK bound at the CBF1 site. Regarding the two B cell-specific
complexes, C2 formation was specifically inhibited by the CBF2
competitor, while C3 formationwas abrogated by the RBP-JK and
CBF2 competitors. These findings strongly suggest that the C3
complex contains RBP-JK bound to the CBF1 site and a second, B
cell-restricted factor bound to the CBF2 site.
To investigate whether the B cell-specific complexes C2 and
C3 contained BSAP/Pax5, the EMSAs were repeated in the
presence of a Pax5 antibody. The addition of the anti-Pax5
antibody greatly reduced the formation of both complexes C2
and C3 (Fig. 1C), clearly indicating that these complexes con-
tain BSAP/Pax5. Note that the anti-Pax5 antibody had no effect
on complex C1 containing RBP-JK. BSAP/Pax5 binding was
confirmed in subsequent experiments using in vitro-translated
(IVT) RBP-JK and BSAP proteins. Thus, incubation of IVT
RBP-JK and BSAP proteins, either singly or in combination,
reproduced the same pattern of protein-DNA complexes as
that observed in the presence of the Rael nuclear extract
(Fig. 1C). Taken together, these data indicate a novel interac-
tion between BSAP/Pax5 and the CBF2 site.
Generation of recombinant EBV genomes carrying Cp dele-
tions. In order to address the contribution of Cp sequences to the
initiation and maintenance of B cell growth transformation, we
constructed a series of recombinant viruses carrying either a
1.3-kb deletion spanning the entire Cp region from positions
429 to846 (CpKO) or a deletion that removed just the E2RE
sequences from positions 429 to 245, which included the
newly identified BSAP/Pax5 site (CpE2REKO) (Fig. 2). These re-
combinant EBV genomes were created from B95.8-derived BAC
construct 2089, which contains 11 copies of the major BamHI
internal repeat, or a 2W derivative carrying just two BamHI W
copies (3, 25, 31). As previously reported (31), we observed a
tendency for the 2089-derived BACs to lose BamHI W repeats
during the recombination process in bacteria (data not shown).
Since our previous studies demonstrated that the number of
BamHI W repeats markedly affects the efficiency of B cell out-
growth, with a minimum of five copies being necessary for opti-
mal growth transformation (31), we therefore selected a series of
2089-derived recombinant BACs, each containing 8 copies of
BamHI W (denoted 8W, 8WCpKO, and 8WE2REKO) for use in
subsequent experiments (Fig. 2). As a control, we also created aCp
revertant in the context of an eight-BamHI W repeat-containing
BAC (8WCp-rev) by homologous recombination of wild-type Cp
sequences with the 8WCpKOBAC. In parallel, two corresponding
series of CpKO and E2REKO recombinants were also created in
the background of the 2W BAC (31).
BACs containing the desired mutations were introduced into
HEK-293 cells, and the transfected cells were selected with hygro-
mycin, before screening of individual clones for high levels of
virus production. Density gradient-purified virus stocks from at
least two different HEK-293 clones were made for each recombi-
nant. No consistent difference was found in virus titers produced
from the different clones, indicating that the introduced Cp mu-
tations had no effect on virus production (data not shown). Like-
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wise there were no consistent differences between the different
virus preparations in virus binding assays (35).
EBV latent-cycle transcription following primary B cell in-
fection.We initially examined the early transcriptional events fol-
lowing B cell infection. CD19-positive B cells were infected at an
MOI of 100 with the panel of wild-type and Cp recombinant
EBVs, and aliquots of infected cells were harvested at intervals of 1,
2, 3, and 5 days for RNA analysis. In order to comprehensively
screen viral transcripts in small numbers of infected cells, viral
RNA was quantified by QPCR analysis using a 48:48 Dynamic
Array (Fluidigm), which allows the simultaneous amplification of
48 samples with 48 different QPCR assays in individual nanoliter-
scale reactions (37). In contrast to previous studies, absolute
quantification of each transcript was achieved by using standard
curves derived from preamplified dilutions of the AQ plasmid,
which contained a single copy of each target amplicon.
The data in Fig. 3 show a subset of results from one represen-
tative experiment measuring EBV gene transcription in B cells
infected with the 8W series of recombinant viruses. Wp-initiated
transcripts were detectable with 8W, 8WE2REKO, and 8WCp-rev
viruses at 1 day postinfection and reached similar levels by day 5,
with up to 4,000 Wp transcripts per ng of RNA (Fig. 3A). How-
ever, themaximal levels ofWp transcripts were about 4-fold lower
in 8WCpKO virus-infected cells. While we were unable to detect
Cp-initiated transcription in cells infected with the 8WCpKO vi-
rus, Cp transcripts from the 8W and 8WCp-rev viruses were read-
ily detectable at 2 days postinfection and steadily increased
throughout the time course, eventually reaching 4,000 to 5,000
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transcripts per ng RNA at day 5 (Fig. 3A); note that these values
were similar to those seen for Wp transcripts. In sharp contrast,
Cp-initiated transcription in cells infected with the 8WE2REKO
virus followed a temporal pattern similar to that seen with the
wild-type virus, but the absolute levels of transcription were10-
fold lower. Thus, the 8WE2REKO virus is clearly impaired in its
ability to activate Cp during the early stages of the infection pro-
cess. Notably, however, the levels of Wp-initiated transcripts with
the 8WE2REKO virus were comparable to those in the wild-type
8W and revertant 8WCp-rev viruses, indicating that Wp activity
had not increased to compensate for reduced levels of Cp activity.
Since our assays measure absolute copy numbers of viral tran-
scripts, we were able to directly compare the levels of Cp- and
Wp-initiated transcripts in infected cells. To allow a clearer com-
parison of promoter usage between different viruses, Wp and Cp
levels were expressed as a percentage of the combined number of
Wp and Cp transcripts (Fig. 3B). In the case of the 8W, 8WE2RE,
and 8WCp-rev viruses, Wp activity accounted for 95 to 100% of
the transcripts at day 1 postinfection. In the case of 8W and
8WCp-rev, the proportion of Wp-initiated transcripts fell sub-
stantially at day 2, which was accompanied by a concomitant in-
crease in the level of Cp transcripts to 30 to 40% of the overall
promoter usage, while at day 3 and day 5 postinfection, the pro-
portion of Cp and Wp usage was approximately similar. In con-
trast, Wp remained the dominant promoter throughout the time
course in cells infected with the 8WE2REKO virus, accounting
for90% of the transcripts.
Wp andCpdrive the transcription of a long primary transcript,
which is subsequently processed to generate the individual EBNA
mRNAs. At early times postinfection, the most abundant mRNA
products in 8W (wild-type)-infected cells were EBNA2 and
BHRF1 (Fig. 3C); transcripts encoding EBNA1 and EBNA3A (Fig.
3C) as well as those encoding EBNA3B and EBNA3C (data not
shown) were also detectable but at much lower levels. Notably,
despite the lack of efficient Cp activation, deletion of the E2RE did
not reduce the overall levels of EBNA and LMP transcripts in
infected cells. In contrast, all the latent genes were transcribed at
lower levels in 8WCpKO-infected cells, consistent with the dimin-
ished levels ofWp activity and the complete absence of Cp activity.
Note that while LMP1 and LMP2A transcript levels remained rel-
atively low during the first 5 days postinfection, as these tran-
scripts reach maximal expression levels only at later times, the
lower level of LMP1 in the 8CpKOvirus is consistent with reduced
expression levels of EBNA2.
Efficiency of B cell transformation. The early transcriptional
events observed in the above-described experiments suggested
that while the E2RE is necessary for efficient activation of Cp tran-
scription, it did not impact latent gene expression during the early
stages of EBV infection.We therefore investigated the importance
of the E2RE for subsequent cell transformation and the establish-
ment of LCLs. B cells were infected at a series of different MOIs
before seeding of 104 cells into wells of a 96-well plate. Cultures
were examined for the presence of transformed foci after 6 weeks.
The results (Fig. 4A) are shown for two different clones of each of
the 8W series of viruses. The 8W wild-type and 8WE2REKO vi-
ruses both transformed B cells very efficiently; the MOIs required
for 50% transformation were 1 for both 8W wild-type clones
and 0.5 and 4.0 for the two 8WE2REKO clones. In contrast, the
8WCpKO virus failed to yield any B cell transformants in this
experiment (Fig. 4A).
In previous work, we showed that viruses with only two copies
of the BamHI W repeat region were impaired for Wp/Cp activa-
tion and B cell transformation (31). We therefore examined
whether deletion of the E2RE would have a more pronounced
effect on B cell transformation in the 2W background. Note that
these transformation assays were carried out at the same time and
on the same batch of primary B cells as the above-described assays
with the 8W series of viruses. As observed for the 8W recombinant
viruses, the 2W wild-type and 2WE2REKO viruses had almost
identical transformation efficiencies, although these efficiencies
were much lower than those for the corresponding 8W viruses
(Fig. 4B). In this particular experiment, there were insufficient
wells with transformed foci to calculate theMOI required for 50%
transformation. As expected from the 8WCpKO results, deletion
of the entire Cp region in the context of this 2W virus also com-
pletely ablated the virus’ growth-transforming capacity.
Although the 8WCpKO viruses failed to yield B cell transfor-
mants in the majority of the 96-well transformation assays de-
scribed above, occasionally we were able to establish LCLs from
rare wells showing transformed foci when B cells were infected at
the highest virus doses. Furthermore, although the 2WCpKO vi-
rus never showed transformation in any of the 96-well assays, on
some occasions wewere able to establish LCLs from the 2WCpKO
virus, as well as from the 8WCpKO virus, from bulk cultures of
infected primary B cells. These cell lines took longer to establish
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FIG 4 Transformation efficiencies of recombinant viruses. (A) Number of
wells from a 96-well plate showing transformed foci within 6 weeks following
exposure to the 8W wild-type or Cp-deleted virus at a range of MOIs. Virus
preparations from two independent HEK-293 producer clones were assayed
for each recombinant. The numbers in parentheses indicate theMOI required
for transformation in 50% of wells. (B) Results of transformation assays using
the 2W, 2WE2REKO, and 2WCpKO viruses.
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than did the LCLs made with the other viruses, as, by microscopic
examination, they represented the outgrowth of a very small num-
ber of transformed cells, unlike the situation with wild-type and
E2REKO viruses, where the majority (8W) or many (2W) of the
cells in each well were transformed. However, once the cultures
were established and had been expanded, there was no obvious dif-
ference in the growth rates between the CpKO LCLs and the others.
The absence of Cp transcripts from the 8WCpKO and 2WCpKO
LCLs, together with hygromycin resistance, confirmed that these
LCLs were genuine CpKO LCLs and not rare, spontaneously trans-
formed LCLs derived from EBV-infected donor B cells.
EBV gene transcription in LCLs established with recombi-
nant Cp viruses. To investigate whether the Cp mutations af-
fected the steady-state levels of Wp and Cp transcripts in estab-
lished transformed lines, we screened an extensive panel of LCLs
generated from different wild-type and mutant viruses; these
LCLs included 12 8W wild-type LCLs, 4 8WE2REKO LCLs, 4
8WCpKOLCLs, 5 2Wwild-type LCLs, 3 2WE2REKOLCLs, and 3
2WCpKO LCLs. Three observations can be made from these data
(Fig. 5). First, there was a broad range in the absolute numbers of
Wp- and Cp-initiated transcripts in wild-type 8W and 2W LCLs.
These data emphasize the fact thatWp activity is readily detectable
in established LCLs and contributes significantly to the overall
levels of EBNA transcription even in the presence of a wild-type
Cp sequence.Moreover, the relative levels of Cp andWpusage are
not significantly altered by the number ofWp copies present in the
EBV genome. Second, deletion of the E2RE always resulted inWp
becoming the dominant promoter, with only very low levels of Cp
transcripts being seen in LCLs derived from the 8WE2REKO and
2WE2REKO viruses. Thus, the pattern of promoter usage seen in
the first few days after infection with E2RE-deleted viruses was
maintained in the established LCLs. Third, in the absence of any
detectable Cp transcription, Wp activity did not apparently in-
crease to compensate.
We then extended the analysis to a subset of these LCLs, two of
each type, using a high-throughput QPCR array to screen a
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broader range of EBV latent- and lytic-cycle transcripts. These
data (Fig. 6) are expressed as EBV transcript copy numbers nor-
malized to the cellular PGK1 expression level. As noted above,
there was considerable variation in the individual transcript levels
between different LCLs, but the values were within the ranges
previously reported for a panel of LCLs analyzed by using this
technology (37). Importantly, with the exception of Cp activity,
there were no consistent differences in the levels of any latent or
lytic transcripts that could be attributed to the Cp mutations. In
conclusion, while deletion of the entire Cp region or just the E2RE
greatly reduces Cp activity during the initial stages of B cell infec-
tion and dramatically decreases transformation efficiency, rare
LCLs carrying thesemutant viruses transcribe the full spectrum of
growth-transforming genes at levels comparable to those in LCLs
derived from a wild-type EBV strain.
DISCUSSION
EBV-induced B cell transformation is characterized by the se-
quential activation of two viral promoters, which drive the expres-
sion of six EBV nuclear antigens and the viral Bcl2 homologue
BHRF1 in latently infected cells. The first promoter to be activated
immediately after infection isWp, present in each of the tandemly
arranged BamHIW repeat sequences. Several cellular factors reg-
ulate transcription initiation from Wp, including the B cell tran-
scription factor BSAP/Pax5, which is absolutely essential for both
Wp activation and B cell transformation in vitro (2, 3, 31). These
Wp-initiated transcripts lead to the expression of EBNA2 and the
subsequent activation of an alternative EBNA promoter, Cp, lo-
cated in the upstream BamHI C region. This raises an important
question, namely, to what extent EBV-induced growth transfor-
mation depends on the activity of Cp, both in the early stages of
the infection process and in established LCLs.
The starting point for this work was a reexamination of a pre-
viously reported observation that Cp reporter constructs are pref-
erentially active in B cell lines (16, 34). This B cell specificity is
achieved, at least in part, by interactions of available cellular fac-
tors with the E2RE (6). In this study, we identified sequence ho-
mology between the BSAP/Pax5 consensus site and sequences
within the Cp E2RE and subsequently demonstrated that BSAP/
Pax5 binds to the E2RE in vitro (Fig. 1). This finding supports the
results of previous DNase I footprinting studies, which revealed
the binding of a lymphocyte-specific factor to this region (7), and
is also consistent with the results of a recent chromatin immuno-
precipitation sequencing (ChIP-Seq) analysis of BSAP/Pax5 bind-
ing across the entire EBV genome (43). This newly identified
BSAP binding site overlaps the CBF2 site, a region previously
shown to be critical for Cp activity (27). Notably, a mutation
within the CBF2 site (27), previously shown to diminish Cp activ-
ity, disrupted BSAP/Pax5 binding (Fig. 1C). Intriguingly, a previ-
ous study reported that the CBF2 site interacted with the cellular
factor AUF1/hnRNPD (15), a result at odds with the results of the
present work, since AUF1 is ubiquitously expressed. Although we
were unable to reproduce the AUF1 interaction using EMSAs
(data not shown), we cannot exclude the possibility that under
certain conditions, AUF1 is recruited to Cp as part of a larger
transcription factor complex that includes BSAP/Pax5. One such
multiprotein complex, containing the B cell transcription factor
Oct2, ARID3A, andE2F1, has been shown to bind toCp sequences
from positions 149 to 109 and mediates EBNA1-dependent
activation of Cp (19). Importantly, our data demonstrate a novel
interaction between BSAP/Pax5 and the E2RE, which provides a
mechanistic basis for the apparent B cell specificity of Cp.
In the next series of experiments, we sought to examine the
effects of specifically deleting the E2RE sequences in the context of
a recombinant virus. Note that it was previously reported that
E2RE-deleted viruses are still capable of inducing B cell transfor-
mation (23, 24). However, those previous studies relied upon
marker rescue experiments using P3HR1-derived recombinants
and were limited in their quantitative analyses of early events dur-
ing the infection process and the efficiency of LCL outgrowth. In
the present work, we have used purified recombinant viruses of
known titers generated by using the EBV BAC system, quantified
promoter usage and gene expression from early times post-B cell
infection through to the establishment of LCLs using QPCR, and
rigorously monitored LCL outgrowth at a range of MOIs (3, 31,
35). Our data confirm that the E2RE plays an important role in
efficiently activatingCpduring the early stages of infection (Fig. 3)
but also show that the E2RE-deletedmutant virus was still capable
of transcribing latent transcripts at levels similar to those of the
wild-type virus. Consistent with these observations, E2RE-dele-
leted recombinants were notmarkedly impaired in B cell transfor-
mation assays in either the 8W or 2W virus background (Fig. 4).
Notably, the absolute levels of Wp-initiated transcripts in-
duced by our E2REKO viruses, either at early stages postinfection
or in established LCLs, were not elevated compared to those in-
duced by wild-type viruses (Fig. 3A and 5A), suggesting that Wp
activity does not simply compensate for reduced levels of Cp tran-
scription. This result contradicts previously reported findings that
Wp transcription is increased in viruses lacking the E2RE (24, 44)
but is consistent with results from another report, which analyzed
the effect of a point mutation in the CBF1/RBP-JK binding site
(23). Interestingly, LCLs derived from E2RE-deleted viruses still
retained low levels of Cp activity, indicating that additional viral
sequences, such as the interaction of oriP with EBNA1, can also
contribute to Cp transcription in the context of the viral genome.
Indeed, a previous study using a recombinant EBV deleted for
amino acids 65 to 89 of EBNA1 demonstrated the importance of
EBNA1 in the activation and maintenance of Cp transcription
(45). Overall, our data argue that while the binding of RBP-JK and
BSAP/Pax5 to Cp is not essential for EBV-induced B cell transfor-
mation, these proteins may cooperate with factors bound to other
regions of Cp (19, 46), ensuring optimal Cp activity and the ex-
pression of the latency III program of viral gene expression in
infected B cells.
In contrast to the situation with the E2RE-deleted viruses, re-
combinants lacking the entire Cp region transformed B cells at
least 100-fold less efficiently than did the wild-type virus (Fig. 4).
Given that E2RE- andCp-deleted viruses are both highly defective
for Cp activity, the dramatic difference in the transforming capac-
ities of these two mutants is surprising. However, this disparity
may reflect the fact that Cp-deleted viruses expressed 3- to 4-fold-
lower numbers of Wp-initiated transcripts during the early stages
of infection, leading to correspondingly reduced levels of EBNA
and BHRF1 transcripts at days 1 to 5 (Fig. 3). Note that there is no
evidence for other unintentional mutations being present in these
Cp-deleted viruses, since Wp levels were restored in a CpKO re-
vertant (Fig. 3A). We speculate that the large 1.4-kb genomic de-
letion potentially disrupted the nucleosomal architecture of the
oriP/Cp/Wp region or altered the position of enhancer sequences,
with a concomitant reduction in Wp activity (47).
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FIG 6 EBV gene transcription in established LCLs infected with recombinant viruses. EBV transcripts from a subset of the wild-type (W), E2REKO (E), and
CpKO (C) 8W and 2W LCLs were quantified by using a 48:48 Dynamic PCR array, and the data were normalized to the cellular PGK1 expression level. Data are
shown for Wp- and Cp-initiated transcripts; the latent transcripts encoding BHRF1 (containing the Y2-HF splice), EBNA2, EBNA3A, EBNA1 (U-K splice),
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data from triplicate RNA samples independently preamplified and tested by QPCR.
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Despite being greatly impaired for B cell transformation, rare
LCLs carrying Cp-deleted viruses were established, and following
expansion, they proliferated in culture at rates similar to those of
wild-type LCLs. These LCLs provide important clues regarding
the relative contribution of Wp and Cp during B cell transforma-
tion. First, our data support previous studies demonstrating that
Cp is dispensable for LCL outgrowth while also clearly showing
that the presence of a functional Cp promoter greatly increases the
transformation efficiency. Second, Cp-deleted LCLs exclusively
usedWp to drive EBNA expression yet expressed steady-state lev-
els of latent transcripts similar to those seen inwild-type LCLs and
E2RE-deleted LCLs (Fig. 5B and 6). In a recent study (37), we
described a method for estimating the absolute number of EBV
transcripts on a per-cell basis. Using the same approach, the most
abundant transcripts in this LCL panel were EBNA2 (median, 87
transcripts per cell), LMP1 (median, 98 transcripts), and latent
BHRF1 (median, 46 transcripts), while EBNA1, EBNA3A, and
LMP2A transcripts were present at much lower levels; impor-
tantly, these values are comparable to those seen previously for a
larger panel of LCLs (37). These findings argue that during clonal
selection following infection with a Cp-deleted virus, there is
strong pressure to maintain sufficient levels of Wp-driven latent
gene expression to support LCL growth. Third, it has been sug-
gested that the switch from Wp to Cp usage is required to ensure
efficient transcriptional elongation of the primary EBV transcript
harboring the EBNA3 and EBNA1 coding sequences located at
least 70 kb downstream of the promoter (48). Our data suggest
that under certain conditions, Wp-initiated transcripts are capa-
ble of efficiently driving the transcription of the downstream
EBNA genes.
The present findings differ from those of a previous study that
reported that Cp deletion did not affect B cell transformation ef-
ficiency (21, 22). That previous study used a virus carrying a larger
3.3-kb deletion, spanning from upstream of the glucocorticoid
response element (GRE) to beyond the Cp transcription start site
(Fig. 1A), and relied on the rescue of transformation-competent
recombinants derived from P3HR1. The recovery of LCLs carry-
ing these Cp-deleted viruses was apparently no less efficient than
that with a control wild-type virus (22). In addition, a cell-free
supernatant containing Cp-deleted recombinant virus produced
from such LCLs infected and transformed fresh B cells as effi-
ciently as the wild-type virus (21, 22). These discrepancies may
reflect technical differences between the two studies. While the
previous study used crude virus preparations, our virus stocks
were density gradient purified and titers were accurately deter-
mined by QPCR to ensure that equivalent MOIs were used in all
experiments, while our virus transformation assays were done
with a range of MOIs. The P3HR1-rescued virus may also have
contained second-site mutations, which could have been selected
during the initial rescue byB cell transformation. Additionally, the
BACs used here are based on the B95.8 EBV strain, which has a
deletion that removes12 kb of sequence compared to wild-type
viruses and the recombinants produced in the P3HR1 system.
Importantly, however, both studies concurred that Cp activity is
dispensable for B cell transformation and demonstrated that es-
tablished LCLs carrying wild-type or Cp-deleted viruses had sim-
ilar levels of latent gene expression (21, 22).
EBV efficiently colonizes the B cell system in vivo through the
transient expression of a series of growth-transforming genes,
which together induce B cell proliferation and ultimately drive the
expansion of a pool of latently infected cells. This growth-trans-
forming program involves the sequential activation of two viral
promoters, Wp and Cp, which are highly conserved among pri-
mate lymphocryptoviruses (49–51), suggesting that these pro-
moters have evolved as part of the virus’ strategy to establish life-
long persistence. By recruiting a key B cell transcription factor,
BSAP/Pax5, both of these promoters may be optimized to ensure
high levels of viral gene transcription in the infected target cell.
While the present work confirms that Wp activity is sufficient for
LCL outgrowth, the efficiency of B cell transformation is greatly
enhanced by the presence of functional Cp sequences.
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